{"id":"carteolol-long-acting-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Systemic beta-blocker effects (bradycardia, bronchospasm)"}]},"_chembl":{"chemblId":"CHEMBL1201002","moleculeType":"Small molecule","molecularWeight":"328.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a beta-blocker applied topically to the eye, carteolol inhibits beta-adrenergic receptors on the ciliary body, which reduces the production and secretion of aqueous humor. This decrease in aqueous humor production lowers intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The long-acting formulation provides sustained drug delivery and prolonged IOP reduction.","oneSentence":"Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:37.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02105285","phase":"PHASE3","title":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":193},{"nctId":"NCT02108288","phase":"PHASE1","title":"Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carteolol long-acting ophthalmic solution","genericName":"Carteolol long-acting ophthalmic solution","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}